![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
U Bickel, OP Schumacher, YS Kang and K Voigt
Institute of Physiology, Philipps University, Marburg, Germany.
To better understand the in vivo pharmacological effects of morphine 3- glucuronide (M3G, a weak opioid antagonist) and morphine 6-glucuronide (M6G, a potent opioid agonist), the permeability of the blood-brain barrier (BBB) for these metabolites was compared with morphine. Tracers were prepared by enzymatic glucuronidation of [N-methyl-3H]morphine. Brain uptake in rats was measured by the internal carotid perfusion technique and after intravenous bolus injections. In the perfusion experiments morphine showed a permeability-surface area product (PS) of 3.52 +/- 0.61 microliter min-1 g-1. Uptake seemed to be mediated by passive diffusion and was not saturable by 100 microM morphine in the perfusate. The BBB permeability of [3H]M3G and [3H]M6G was too low to be quantified after 5 min of perfusion. Brain uptake of [3H]M3G and [3H]M6G 60 min after i.v. bolus injection reached 0.0060 +/- 0.0003% and 0.0030 +/- 0.0005% injected dose per g, respectively. From these brain concentrations and the corresponding plasma concentration-time curves, BBB PS values of 0.14 +/- 0.02 microliter min-1 g-1 and 0.11 +/- 0.01 microliter min-1 g-1, respectively, were calculated. The ratio of BBB PS values is complementary to the analgesic potencies of morphine and M6G after different routes of administration. The low PS of M6G explains why it is approximately equipotent to morphine after systemic injection, although it is about 2 orders of magnitude more potent than morphine after administration directly into the central nervous system.
This article has been cited by other articles:
|
|
 |
|
  E. Bostrom, U. S. H. Simonsson, and M. Hammarlund-Udenaes In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics Drug Metab. Dispos., September 1, 2006; 34(9): 1624 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. A. van Dorp, R. Romberg, E. Sarton, J. G. Bovill, and A. Dahan Morphine-6-Glucuronide: Morphine's Successor for Postoperative Pain Relief? Anesth. Analg., June 1, 2006; 102(6): 1789 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Temsamani, C. Bonnafous, C. Rousselle, Y. Fraisse, P. Clair, L.-A. Granier, A. R. Rees, M. Kaczorek, and J.-M. Scherrmann Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 712 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Tegeder, S. Meier, M. Burian, H. Schmidt, G. Geisslinger, and J. Lotsch Peripheral opioid analgesia in experimental human pain models Brain, May 1, 2003; 126(5): 1092 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Osburg, C. Peiser, D. Domling, L. Schomburg, Y. T. Ko, K. Voigt, and U. Bickel Effect of endotoxin on expression of TNF receptors and transport of TNF-alpha at the blood-brain barrier of the rat Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E899 - E908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Platt, J. K. Rowlett, and R. D. Spealman Discriminative Stimulus Effects of Intravenous Heroin and Its Metabolites in Rhesus Monkeys: Opioid and Dopaminergic Mechanisms J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohmori, T. Hayashi, M. Kawase, S. Saito, and Y. Morimoto Pharmacokinetic and Pharmacodynamic Evaluations of a Potent Analgesic, Dihydroetorphine, in Hairless Rat J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 528 - 536. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. C. Chang, M. I. Churchwell, K. B. Delclos, R. R. Newbold, and D. R. Doerge Mass Spectrometric Determination of Genistein Tissue Distribution in Diet-Exposed Sprague-Dawley Rats J. Nutr., August 1, 2000; 130(8): 1963 - 1970. [Abstract] [Full Text]
|
|
|
|
|
|
S. P. Letrent, G. M. Pollack, K. R. Brouwer, and K. L.R. Brouwer Effects of a Potent and Specific P-Glycoprotein Inhibitor on the Blood-Brain Barrier Distribution and Antinociceptive Effect of Morphine in the Rat Drug Metab. Dispos., July 1, 1999; 27(7): 827 - 834. [Abstract] [Full Text]
|
|
|
|
|
|
D. Wu, Y.-S. Kang, U. Bickel, and W. M. Pardridge Blood-Brain Barrier Permeability to Morphine-6-Glucuronide is Markedly Reduced Compared with Morphine Drug Metab. Dispos., June 1, 1997; 25(6): 768 - 771. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Huwyler, D. Wu, and W. M. Pardridge Brain drug delivery of small molecules using immunoliposomes PNAS, November 26, 1996; 93(24): 14164 - 14169. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
